ALB and neoplasm: In univariate analysis, the following factors correlated with shorter PFS (Table 2a): lack of resection of residual disease during imatinib therapy, primary tumor located in duodenum or intraperitoneally with unknown primary origin, the maximal tumor diameter of the largest tumor >100 mm, tumor mutation other than KIT exon 11, the younger age, low baseline albumin level, high baseline neutrophils count, low baseline hemoglobin level, and poor performance status.